Tesaro

Tesaro is a pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.
History.
Tesaro was founded in 2010. The company's first commercial product, Varubi, was approved by the FDA in October 2015. As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD. The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA. In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer. On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale. On December 3, 2018, GlaxoSmithKline announced it would acquire the company for $5.1 billion, and the deal was completed on January 22, 2019.